CD274 and cancer: Since 2014, the US FDA has approved six PD-1/PD-L1 inhibitors for cancer treatment, all of them being monoclonal antibody drugs, including pembrolizumab, nivolumab, duvalumab, atezolizumab, avelumab, and cemiplimab.